BIOGAZELLE (CellCarta)

Company Snapshot

Founded: 2019
Entity Type: Private
Region: Canada
Headquarter: Quebec, Canada
Key Geographics: North America, Europe, Australia, Asia
Corporate Address: 201 President Kennedy Avenue Suite 3900, Montreal Quebec, Canada H2X 3Y7 Tel. +1-(514)-360-3600 www.cellcarta.com

Company Overview

Biogazelle is developing RNA-based diagnostics that use qPCR technologies. The company is active in discovering and using liquid biopsy RNA biomarkers.

For liquid biopsy, Biogazelle markets a range of targeted tests that can be applied on cell-free or circulating DNA for detecting and quantifying specific genomic aberrations. Biomarkers emphasized include messenger RNA, microRNA and long non-coding RNA.

BIOGAZELLE (CellCarta) In Reports

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

BCC Market Research Report for global liquid biopsy research tools, liquid biopsy biomarkers, technologies, services and diagnostics markets.

Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023

Get an overview of the global markets for liquid biopsy technologies, applications, industry subsegments along with analyses of global market trends with data from 2017, 2018 and projections of CAGRs through 2023 ...

Liquid Biopsy with Emphasis on NIPT: Global Markets to 2023

The global NIPT market was valued at $1.9 billion in 2018 & is projected to grow at a CAGR of 14.1% to reach a forecast size of $3.7 billion by 2023. Also get insight into liquid biopsy Market.

Company's Business Segments

  • RNA Profiling : The company provides RNA profiling information using next-generation sequencing (NGS) with the appropriate platforms to tackle any sequencing project size (NovaSeq X Plus, NovaSeq 6000, NextSeq 550Dx). It also offers access to a broad range of biomarker platforms and services.

Applications/End User Industries

  • Healthcare
  • Biopharmaceutical
AI Sentiment